Search

Your search keyword '"Sulkowski, Mark S"' showing total 40 results

Search Constraints

Start Over You searched for: Author "Sulkowski, Mark S" Remove constraint Author: "Sulkowski, Mark S" Journal hepatology Remove constraint Journal: hepatology
40 results on '"Sulkowski, Mark S"'

Search Results

1. Reply

2. Safety and efficacy of current direct‐acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV‐TARGET study

4. Safety and Efficacy of Ledipasvir-Sofosbuvir in Black Patients with Hepatitis C Virus Infection: A Retrospective Analysis of Phase 3 Data

5. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus

7. Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus

8. Efficacy and safety of MK-5172 + MK-8742 ± ribavirin in HCV mono-infected and HIV/HCV co-infected treatment-naïve, non-cirrhotic patients with hepatitis C virus genotype 1 infection: The C-WORTHY study (Final results, Parts A and B): 236

11. An Integrated Safety and Efficacy Analysis of >500 Patients with Compensated Cirrhosis Treated with Ledip-asvir/Sofosbuvir with or without Ribavirin: 82

13. All-Oral Combination of Ledipasvir, Vedroprevir, Tegobuvir, and Ribavirin in Treatment-Naïve Patients With Genotype 1 HCV Infection

16. Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trial

18. Anemia during treatment with peginterferon Alfa-2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial

23. Daclatasvir, an NS5A Replication Complex Inhibitor, Combined With Peginterferon Alfa-2a and Ribavirin in Treatment-Naive HCV-Genotype 1 or 4 Subjects: Phase 2b COMMAND-1 SVR12 Results: 755

27. Racial differences in hepatitis C treatment eligibility

29. Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct‐acting antiviral treatment

30. Safety and efficacy of ledipasvir‐sofosbuvir in black patients with hepatitis C virus infection: A retrospective analysis of phase 3 data

31. Concordance of sustained virological response 4, 12, and 24 weeks post‐treatment with sofosbuvir‐containing regimens for hepatitis C virus

32. Hepatitis C trials that combine investigational agents with pegylated interferon should be stratified by interleukin-28B genotype

33. Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy

37. Reply

Catalog

Books, media, physical & digital resources